Roche Holding AG Logo

Roche Holding AG

A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.

RO | SW

Overview

Corporate Details

ISIN(s):
CH0012032048 (+1 more)
LEI:
549300U41AUUVOAAOB37
Country:
Switzerland
Address:
Grenzacherstr. 124, 4058 Basel
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Roche Holding AG is a global, research-based healthcare company operating through two primary divisions: Pharmaceuticals and Diagnostics. As one of the world's largest biotechnology companies, Roche is a leading provider of innovative cancer treatments and a key developer of medicines for viral infections and cardiometabolic diseases. The Diagnostics division focuses on providing in-vitro diagnostic tests and transformative solutions that support early detection, prevention, diagnosis, and treatment monitoring. By combining its strengths in both pharmaceuticals and diagnostics, Roche aims to advance personalized healthcare and improve patient outcomes worldwide through scientific innovation and digital health solutions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2004-12-31 00:00
Annual Report
Annual Report 2004
English 8.5 MB
2004-12-31 00:00
Annual Report
Jahresbericht 2004
German 8.8 MB
2004-04-22 00:00
Investor Presentation
Presentation to analysts First Quarter 2004 Basle, April 21, 2004
English 1.2 MB
2003-12-31 00:00
Annual Report
Annual Report 2003
English 8.4 MB
2003-12-31 00:00
Annual Report
Jahresbericht 2003
German 8.5 MB
2003-07-25 00:00
Investor Presentation
First Half 2003 Presentation to analysts
English 1.1 MB
2003-04-11 00:00
Investor Presentation
26 March 2003Roadshow USANew York
English 175.9 KB
2003-04-10 00:00
Investor Presentation
Company Presentation 2003
English 250.3 KB
2003-02-12 00:00
Investor Presentation
16 January 2003 Roadshow Germany
English 323.7 KB
2002-12-31 00:00
Annual Report
Annual Report 2002
English 9.3 MB
2002-12-31 00:00
Annual Report
Jahresbericht 2002
German 9.7 MB

Automate Your Workflow. Get a real-time feed of all Roche Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Roche Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Roche Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-16 N/A Executive member Sell None 1,494,248.20 CHF
2025-02-07 N/A Non-Executive member Buy None 613,652.00 CHF
2024-07-26 N/A Non-Executive member Sell None 1,743,760.00 CHF
2024-07-25 N/A Non-Executive member Sell None 723,460.00 CHF
2024-06-21 N/A Executive member Sell None 2,220,432.00 CHF
2024-06-10 N/A Executive member Sell None 1,260,138.00 CHF
2024-05-29 N/A Non-Executive member Buy None 504,400.00 CHF

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.